← Eichor
Condition: All Recurrent Adult Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: All Recurrent Adult

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

CAR-T Cell Therapy for ALL
EARLY_Phase 1 · 1 location(s) · Dr. Zaineb Akram · NCT07695012Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, o
Phase 2 · 278 location(s) · National Cancer Institute (NCI) · NCT03739814CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A
Phase 2 · 2 location(s) · KK Women's and Children's Hospital · NCT05648019HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Ste
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03326921Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Phase 1 · 1 location(s) · Stanford University · NCT06408194HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relaps
Phase 1/Phase 2 · 33 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05751044Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Phase 2 · 1 location(s) · New York Medical College · NCT02393157Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Rela
Phase 1/Phase 2 · 33 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05745714VHAG in Treating R/R T-ALL/LBL
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06742463BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
Phase 1/Phase 2 · 6 location(s) · BlueSphere Bio, Inc · NCT06704152Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggr
Phase 1/Phase 2 · 6 location(s) · University of Alberta · NCT039389873'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma
Phase 1/Phase 2 · 5 location(s) · Otsuka Medical Devices Co., Ltd. Japan · NCT07075328HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignanci
Phase 1/Phase 2 · 36 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05658640Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refrac
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT07133997Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Phase 2 · 2 location(s) · Yale University · NCT05996185CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05442515Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Ly
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03136146Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphoma
Phase 1 · 1 location(s) · John Reneau · NCT04848064CD7 CAR-T Cells in T-cell Lymphoma/Leukemia
NA · 1 location(s) · Shenzhen University General Hospital · NCT05620680Venetoclax Basket Trial for High Risk Hematologic Malignancies
Phase 1 · 5 location(s) · Andrew E. Place, MD · NCT05292664CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
Phase 1 · 2 location(s) · Rong Tao · NCT06445803Study of Out of Specification for Tisagenlecleucel
Phase 3 · 54 location(s) · Novartis Pharmaceuticals · NCT04094311Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive
Phase 2 · 157 location(s) · Children's Oncology Group · NCT02981628Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cel
NA · 1 location(s) · Peking University People's Hospital · NCT06581081
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.